Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ONS 44th Annual Congress /
PARP inhibitors and their side effects in solid tumour therapy

11th - 14th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 2642

Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA

Paula Anastasia speaks to ecancer at ONS 2019 about the changing paradigms of treating solid tumours with PARP inhibitors.

She proposes that, in order to get patients to report their side effects to nurses, patients need to be better educated about the treatment the are receiving. She explains that some patients are hesitant to talk to oncology nurses about their side effects as the fear it will result in dose reductions or dose holding, which might mean less efficacy - but this is not the case.

Paula speaks about some of the PARP inhibitors available for not only ovarian cancer but also metastatic breast cancer, the importance of genetic testing and what might be next for these therapies.

This programme has been supported by an unrestricted educational grant from Pfizer. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation